Healthcare's persistent underperformance over the past two years has been a challenging narrative for investors, with political uncertainty, rising interest rates, and the allure of AI and technology stocks contributing to its struggles. However, beneath the surface, the healthcare sector is a story of resilience and innovation, offering a compelling opportunity for wealth allocators in Asia. This article delves into the key factors driving the sector's potential, the valuation disconnect, and the role of innovation and M&A in shaping its future.
A Sector in Transition
The healthcare sector's performance has been a rollercoaster ride, with political headwinds and the tech sector's dominance casting a long shadow. Marcel Fritsch, Head of Healthcare Funds and Mandates at Bellevue Asset Management, acknowledges the sector's challenges, attributing them to political uncertainty and the surge in AI and tech investments. However, he emphasizes that the sector's fundamentals remain robust, with strong earnings quality and revenue growth across multiple sub-sectors.
The valuation disconnect is a key theme. Healthcare equities trade at a discount to the broader market, with the MSCI World Healthcare Index trading at 17 times forward earnings compared to 21 times for the S&P 500. This undervaluation presents an opportunity for investors, as the capital flowing into technology and AI must come from somewhere, and healthcare is among the sectors that have been left behind.
Innovation as the Growth Engine
Innovation is the lifeblood of the healthcare sector, and it is creating entirely new revenue pools. In cardiovascular medicine, lipoprotein(a) (Lp(a)) represents a multi-billion-dollar opportunity, with several companies in late-stage trials. Robotic surgery is another area of structural advance, with Intuitive Surgical's Da Vinci 5 system incorporating AI-driven features. The continuous glucose monitoring market is projected to grow from USD11.7 billion in 2024 to USD21.3 billion by 2029, while soft-tissue surgical robotics is expected to more than double from USD8.7 billion to USD19.1 billion over the same period.
AI as Enabler, Not Disruptor
Artificial intelligence (AI) is emerging as a cost and efficiency lever across drug development, clinical trials, and surgical systems. In pharma and biotech, AI is being deployed to accelerate drug development, improve patient selection for clinical trials, and predict toxicity profiles earlier in the process. For health insurance companies, AI enables automation of invoice processing and contract management at scale. In medtech, heavy regulatory requirements around clinical data and device approvals create natural barriers that protect hardware-based businesses from software disruption.
M&A as a Structural Imperative
Patent expirations loom large over big pharma, with hundreds of billions of dollars in revenue at risk over the next four to six years. M&A is an imperative rather than an option, with the 20 largest biopharma companies collectively holding more than USD1 trillion in combined cash and additional debt capacity. Major transactions in 2025 and early 2026 underscore that the cycle is well underway, with medtech M&A also accelerating.
Building the Case for Allocation
For wealth managers and family office professionals, healthcare remains structurally underweight in most portfolios. However, the sector's defensive qualities and innovation-driven growth make it an increasingly logical complement to concentrated technology positions. As one multi-family office representative put it, healthcare is one of the best sectors for the current generation because of the domain expertise required. With vehicles covering broad healthcare, medtech, and services, and emerging markets healthcare, Bellevue Asset Management positions itself as a specialist partner for investors seeking differentiated healthcare exposure.
In conclusion, the healthcare sector is a story of resilience and innovation, offering a compelling opportunity for wealth allocators in Asia. The valuation disconnect, combined with the sector's strong fundamentals and innovation-driven growth, makes it an attractive investment opportunity. As the sector transitions, investors who take a disciplined approach and focus on innovation and M&A will be well-positioned to capitalize on the sector's potential.
